Antifibrillatory effect of esmolol alone and in combination with lidocaine

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 3, 1996, Pages 376-382

  Tisdale, James E ^b   Sun, He ^d   Zhao, Hong ^d   Fan, Cheng De ^d   Colucci, Robert D ^c   Kluger, Jeffrey ^d   Chow, Moses S S ^a  

^a HARTFORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NONE

Author keywords

Combined drug therapy; Esmolol; Lidocaine; Pigs; Ventricular fibrillation threshold

Indexed keywords

ESMOLOL; LIDOCAINE;

ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; ELECTROSTIMULATION; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SWINE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HEART RATE; LIDOCAINE; PROPANOLAMINES; SWINE; VENTRICULAR FIBRILLATION;

EID: 0030030933     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199603000-00010     Document Type: Article

References (39)

1. Vaughan Williams EM. A classification of antiarrhythmic drug actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-47.
2. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Adult advanced cardiac life support. JAMA 1992;268:2199-241.
3. Spear JE, Moore EN, Gerstenblith G. Effect of lidocaine on the ventricular fibrillation threshold in the dog during acute ischemia and premature ventricular contractions. Circulation 1972;46:65-73.
4. Kniffen FJ, Lomas TE, Nobel-Allen NL, Lucchesi BR. The comparative antiarrhythmic actions of lidocaine and its quaternary derivative, methyl lidocaine. Circulation 1974;49: 264-71.
5. Alien JD, Jannes RGG, Kelly JG, Shanks RG, Zaide SA. Comparison of the effects of lignocaine and mexiletine on experimental ventricular arrhythmias. Postgrad Med J 1977; 53(suppl 1):35-45.
6. Chow MSS, Kluger J, DiPersio DM, Lawrence R, Fieldman A. Antifibrillatory effects of lidocaine and bretylium immediately postcardiopulmonary resuscitation. Am Heart J 1985;110:938-43.
7. Lie KI, Wellens HJ, van Capelle FJ, Durrer D. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind randomized study of 212 consecutive patients. N Engl J Med 1974;291:1324-6.
8. Holder DA, Sniderman AD, Fraser G, Fallen EL. Experience with bretylium tosylate by a hospital cardiac arrest team. Circulation 1977;55:541-4.
9. Bernstein JG, Koch-Weser J. Effectiveness of bretylium tosylate against refractory ventricular arrhythmias. Circulation 1972;45:1024-34.
10. Anderson JL. Bretylium tosylate: profile of the only available class III antiarrhythmic agent. Clin Ther 1985;7:205-24.
11. Garrett ER, Green JR, Bialer M. Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration. Biopharm Drug Dispos 1982;3: 129-64.
12. Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, Lai C-M. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther 1983;34: 427-34.
13. The Esmolol vs Placebo Multicenter Study Group. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986;11:42-8.
14. Barth C, Ojile M, Pearson AC, Labovitz AJ. Ultra short-acting intravenous β-adrenergic blockade as add-on therapy in acute unstable angina. Am Heart J 1991;121:782-8.
15. Labovitz AJ, Barth C, Castello R, Ojile M, Kern MJ. Attenuation of myocardial ischemia during coronary occlusion by ultrashort-acting beta adrenergic blockade. Am Heart J 1991;121:1347-52.
16. Hohnloser SH, Meinertz T, Klingenheben T, Sydow B, Just H. Usefulness of esmolol in unstable angina pectoris. Am J Cardiol 1991;67:1319-23.
17. Wallis DL, Wedel VA, Scanlon PJ, Euler DE. Effects of esmolol on the ventricular fibrillation threshold. Pharmacology 1988;36:9-15.
18. Guarnieri T, Merillat JC, Singer I, Siddoway LA, Moore EN, Levine JH. Esmolol elevates the ventricular fibrillation threshold in humans during automatic defibrillator testing [Abstract]. J Am Coll Cardiol 1988:11:181.
19. van Dantzig JM, Koster RW, Biervliet JD. Treatment with esmolol of ventricular fibrillation unresponsive to lidocaine and procainamide. J Cardiothorac Vasc Anesth 1991;5: 600-3.
20. Raeder EA, Verrier RL, Lown B. Protective effect of tiapamil against ventricular fibrillation during coronary artery occlusion. Am Heart J 1986;111:878-82.
21. Rogers RM, Spear JF, Moore EN, Horowitz LH, Sonne JE. Vulnerability of canine ventricle to fibrillation during hypoxia and respiratory acidosis. Chest 1973;63:986-94.
22. Achari R, Drissel D, Thomas D, Shin K, Look Z. Analysis of esmolol in human blood by high-performance liquid chromatography and its application to pharmacokinetic studies. J Chromatogr 1988;424:430-4.
23. Fan CD, Zhao H, Chow MS. Simple and rapid high-performance liquid Chromatographic assay for esmolol. J Chromatogr 1991;570:217-23.
24. Nation RL, Peng CW, Chiou WL. High-performance liquid Chromatographic method for the simultaneous determination of lidocaine and its N-dealkylated metabolites in plasma. J Chromatogr 1979;162:466-73.
25. Coram WM, Olson AW, Beil ME, Cabot CF, Weiss GB. Effects of metoprolol, alone and in combination with lidocaine, on ventricular fibrillation threshold: comparison with atenolol, propranolol, and pindolol. J Cardiovasc Pharmacol 1987;9:611-21.
26. de Langen CDJ, Balke CW, Spear JF, Levine JH, Moore EN. Interaction of metoprolol and lidocaine on the ventricular fibrillation threshold in the anesthetized dog. J Cardiovasc Pharmacol 1988;12:683-8.
27. Coltart DJ, Meldrum SJ. The effect of propranolol on the human and canine transmembrane action potential [Abstract]. Br J Pharmacol 1970;40:148P.
28. Reynolds RD, Gorczynski RJ, Quon CY. Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol 1986;26 (suppl A):A3-14.
29. Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51:1196-202.
30. Nanas JN, Kralios AC. Relative effects of propranolol and timolol on ventricular fibrillation threshold and hemodynamics in the dog. Am Heart J 1986;111:1094-100.
31. Gang ES, Bigger JT, Uhl EW. Effects of timolol and propranolol on inducible sustained ventricular tachyarrhythmias in dogs with subacute myocardial infarction. Am J Cardiol 1984;53:275-81.
32. Spear JF, Moore EN, Ricciutti M. The effects of d- and l-optical isomers of propranolol on the ventricular fibrillation threshold. Eur J Cardiol 1978;7:117-22.
33. Raeder EA, Verrier RL. Lown B, Intrinsic sympathomimetic activity and the effects of beta-adrenergic blocking drugs on vulnerability to ventricular fibrillation. J Am Coll Cardiol 1983;1:1442-9.
34. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981;6:429-53.
35. Gorczynski RJ. Basic pharmacology of esmolol. Am J Cardiol 1985;56:3F-13F.
36. Shaffer JE, Quon CY, Gorczynski RJ. β-Adrenoreceptor antagonist potency and pharmacodynamics of ASL-8123, the primary acid metabolite of esmolol. J Cardiovasc Pharmacol 1988;11:187-92.
37. Sintetos AL, Hulse J, Pritchett ELC. Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus. Clin Pharmacol Ther 1987;41:112-7.
38. Mayer O, Cepelak V, Vitous J, Potmesil J. Beta-blocking drug metipranolol: plasma levels and pharmacodynamic action in man. Int J Clin Pharmacol Ther Toxicol 1980;18:113-20.
39. Collett JT, Hendrickson JA, Chew CYC, Shah PM, Laddu AR, Singh BN. Comparative beta-blocking properties of acebutolol and propranolol relative to plasma levels. Int J Clin Pharmacol Ther Toxicol 1981;19:473-8.